ICE Bioscience Inc., established in 2010 in Beijing, focuses on an integrated biological services platform for innovative drug discovery, encompassing target identification and validation, lead compound screening, optimization, and pre-clinical candidate stages. It pioneers an innovative CRO+ model in biological and pharmacological research technologies across oncology, immunology, cardiovascular, central nervous system, and metabolism diseases.
ICE Bioscience expert electrophysiology team has led the way in early drug discovery since 2010, specializing in ion channel screening and cardiac safety assessment. Our reputation is built on comprehensive services from target validation to preclinical candidate identification.
ICE Bioscience Protein Science Platform offers integrated custom protein services, including cloning, expression, purification, quality control, and activity determination. The platform boasts over 1200 enzymatic assays, 700 target protein products, and more than 50 validated SPR assays, supporting new drug development for global partners.
Unlock the frontiers of drug discovery with ICE Bioscience, where our exceptional capabilities in GPCR drug discovery support you through every critical step, from target validation to the identification of pre-clinical candidates. Our comprehensive GPCR screening and assay development services are designed to accelerate innovations, supporting drug discovery teams in identifying and optimizing promising GPCR-targeted therapies.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
